Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn’s disease treated with anti-tumor necrosis factor antibodies-Reference-Cited by-同舟云学术

Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn’s disease treated with anti-tumor necrosis factor antibodies

Published:2015-05-20 Issue:1 Volume:5 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Eder Piotr,Michalak Michal,Katulska Katarzyna,Lykowska-Szuber Liliana,Krela-Kazmierczak Iwona,Stawczyk-Eder Kamila,Klimczak Katarzyna,Szymczak Aleksandra,Linke Krzysztof

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep10223.pdf

Reference45 articles.

1. Feagan, B. G. et al. Recommendations for the treatment of Crohn’s disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm. Bowel Dis. 1, 152–160 (2012).

2. Allez, M. et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J. Crohns Colitis 4, 355–366 (2010).

3. Vermeire, S. & Gils, A. Value of drug level testing and antibody assays in optimizing biological therapy. Frontline Gastroenterology 4, 41–43 (2013).

4. Siegel, C. A. & Melmed, G. Y. Predicting response to anti-TNF agents for the treatment of Crohn’s disease. Ther. Adv. Gastroenterol. 2, 245–251 (2009).

5. Amitai, M., Ben-Horin, S., Eliakim, R. & Kopylow, U. Magnetic resonance enterography in Crohn’s disease: a guide to common imaging manifestations for the IBD physician. J. Crohns Colitis 8, 603–615 (2013).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease;New England Journal of Medicine;2024-07-18

2. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study);Frontiers in Pharmacology;2023-10-09

3. Predicting Treatment Response in Inflammatory Bowel Diseases: Cross-Sectional Imaging Markers;Journal of Clinical Medicine;2023-09-12

4. Using MR Enterography and CT Enterography for Routine Crohn’s Surveillance: How We Do It Now, and How We Hope to Do it in the Future;Korean Journal of Radiology;2022

5. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?;Journal of Clinical Medicine;2021-11-15